Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Status:
Recruiting
Trial end date:
2023-10-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the long-term safety of rimegepant in the acute
treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of
age).